Jpmorgan Chase & CO Protalix Bio Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,595 shares of PLX stock, worth $2,918. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,595
Previous 1,595
-0.0%
Holding current value
$2,918
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PLX
# of Institutions
50Shares Held
3.58MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$1.75 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$796,4390.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$683,9750.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$609,7020.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$494,1000.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $91M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...